The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
Guidelines
June 2017
HIV strategic information for impact
PQDx 0179-012-00 WHO
PQDx Public Report
June/2017, version 4.0
PQDx 0144-043-00 WHO
PQDx Public Report
November/2016, version 4.0
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0183‐060‐00 WHO
PQ Public Report
October/2016, version 5.0
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
PQDx 0018-010-00 WHO
PQDx PR
July/2016, version 3.0
PQDx 0005-005-00
WHO PQDx PR
May/2016, version 3.0
PLOS ONE | https://doi.org/10.1371/journal.pone.0192765 February 23, 2018
HIV testing
Policy Brief
July 2015
It's time to deliver differently.
Accessed: 13.11.2019
The primary role of Benin’s Department of Pharmacy and Medicines (DPMED) is to develop and apply the national pharmaceutical policy. The main objective of this policy is to ensure the availability and accessibility of quality medicines for the population. To fulfill its mandate, DPMED aims to stre...ngthen its regulatory capacity, including the issuance of licenses to pharmaceutical establishments and the registration of pharmaceutical products. Benin’s current registration system shares core concerns that are common to most developing countries, notably the capacity to evaluate and monitor the security, efficacy, and quality of medicines and other health products. It is currently characterized by 1) poor or inadequate traceability of records or regulations (example: a product’s marketing authorization [MA] is often hard to find); 2) lack of evidence used in the regulatory decision-making process (reasons behind special import authorization, i.e., products without valid MAs); 3) inconsistent and unsecured archiving system; 4) limited human resources; and 5) an inefficient information management system
more
WHO Progress Brief
Progress Brief
July 2017
2010/4 Vol. 22 | pages 425 à 435
ISSN 0995-3914
La reproduction ou représentation de cet article, notamment par photocopie, n'est autorisée que dans les
limites des conditions générales d'utilisation du site ou, le cas échéant, des conditions générales de la
licence souscrite par votr...e établissement. Toute autre reproduction ou représentation, en tout ou partie,
sous quelque forme et de quelque manière que ce soit, est interdite sauf accord préalable et écrit de
l'éditeur, en dehors des cas prévus par la législation en vigueur en France. Il est précisé que son stockage
dans une base de données est également interdit.
more
Washington, D.C., USA, 23-27 September 2018
Provisional Agenda Item 4.6
CD56/10, Rev. 1 31 August 2018
Original: Spanish